Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
- 27 April 2012
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (4) , 641-647
Abstract
Pretreatment detection of peripheral blood malignant circulating plasma cells (CPCs) has been shown to be of negative prognostic value in multiple myeloma (MM). We hypothesized that the assessment of CPC kinetics in response to one therapy cycle using six-color flow cytometry could be helpful in the early detection of MM refractoriness to treatment. Forty-two patients with refractory or relapsed (RR) MM were enrolled. Median time to tumor progression (TTP) of 51 days and median overall survival (OS) of 308 days was shortest in patients whose CPCs with aberrant phentoype (aCPCs) did not decrease after one therapy cycle compared to patients with decreasing (median TTP 258 days and OS 856 days) or undetectable (median TTP 581 days and OS 1006 days) aCPCs (p < 0.001 and p = 0.007 for TTP and OS, respectively). Non-reduction of aCPCs in patients with RR MM after the first cycle of therapy may be useful in early identification of patients resistant to a given therapy.Keywords
This publication has 30 references indexed in Scilit:
- The role of complete response in multiple myelomaBlood, 2009
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaBritish Journal of Haematology, 2008
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersHaematologica, 2008
- Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myelomaHaematologica, 2007
- Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyJournal of Clinical Oncology, 2007
- Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patientsBone Marrow Transplantation, 2006
- Impact of complete remission with intensive therapy in patients with responsive multiple myelomaBone Marrow Transplantation, 2001
- High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institutionBone Marrow Transplantation, 2000
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996